1 | quality policy newsroom partnering | | | | | | | 3 | 0.84% |
2 | company about us our | | | | | | | 3 | 0.84% |
3 | newsroom partnering contact us | | | | | | | 3 | 0.84% |
4 | biopas disease areas responsability | | | | | | | 3 | 0.84% |
5 | values why biopas disease | | | | | | | 3 | 0.84% |
6 | us our values why | | | | | | | 3 | 0.84% |
7 | about us our values | | | | | | | 3 | 0.84% |
8 | our values why biopas | | | | | | | 3 | 0.84% |
9 | our company about us | | | | | | | 3 | 0.84% |
10 | for patients in latin | | | | | | | 2 | 0.56% |
11 | is a leading and | | | | | | | 2 | 0.56% |
12 | marketing and selling of | | | | | | | 2 | 0.56% |
13 | all of latin america | | | | | | | 2 | 0.56% |
14 | and orphan drugs and | | | | | | | 2 | 0.56% |
15 | oncology and orphan drugs | | | | | | | 2 | 0.56% |
16 | dermatology oncology and orphan | | | | | | | 2 | 0.56% |
17 | patients in latin america | | | | | | | 2 | 0.56% |
18 | immunology dermatology oncology and | | | | | | | 2 | 0.56% |
19 | company holds leading positions | | | | | | | 2 | 0.56% |
20 | in latin america biopas | | | | | | | 2 | 0.56% |
21 | the company holds leading | | | | | | | 2 | 0.56% |
22 | and more than 250 | | | | | | | 2 | 0.56% |
23 | products the company holds | | | | | | | 2 | 0.56% |
24 | pharmaceutical products the company | | | | | | | 2 | 0.56% |
25 | inlicensing marketing and selling | | | | | | | 2 | 0.56% |
26 | and selling of cuttingedge | | | | | | | 2 | 0.56% |
27 | contact us × our | | | | | | | 2 | 0.56% |
28 | partnering contact us × | | | | | | | 2 | 0.56% |
29 | differentiated latin american pharmaceutical | | | | | | | 2 | 0.56% |
30 | with fully owned subsidiaries | | | | | | | 2 | 0.56% |
31 | fully owned subsidiaries and | | | | | | | 2 | 0.56% |
32 | owned subsidiaries and more | | | | | | | 2 | 0.56% |
33 | why biopas disease areas | | | | | | | 2 | 0.56% |
34 | disease areas responsability pharmacovigilance | | | | | | | 2 | 0.56% |
35 | areas responsability pharmacovigilance compliance | | | | | | | 2 | 0.56% |
36 | subsidiaries and more than | | | | | | | 2 | 0.56% |
37 | pharmacovigilance compliance quality policy | | | | | | | 2 | 0.56% |
38 | compliance quality policy newsroom | | | | | | | 2 | 0.56% |
39 | policy newsroom partnering contact | | | | | | | 2 | 0.56% |
40 | our disease areas newsroom | | | | | | | 1 | 0.28% |